Management of patients presenting with generalized musculoskeletal pain and a suspicion of Lyme disease

Garnier, Stéphanie Ranque; Eldin, Carole; Sault, C.; Raoult, Didier; Donnet, Anne

doi:10.1016/j.medmal.2019.01.008

Cited by 6 publications

(7 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Guedj et al Proposed that functional neuroimaging can be used for auxiliary diagnosis and treatment of PTLDS patients with somatic disorders [10]. Ranque-Garnier et al Proposed that genetics could help the treatment of PTLD [23]. Klempner et al Proposed that neurotrophic drugs can also be used to reduce the nerve injury caused by nerve symptoms from PTLDS [17].…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis

et al. 2023

View full text Add to dashboard Cite

Background At present, the pathogenesis of post-treatment Lyme disease (PTLDS) is not clear, so the treatment scheme of PTLDS, especially antibiotic treatment, is still controversial. This study aims to evaluate the efficacy of antibiotics in the treatment of PTLDS using network meta-analysis (NMA). Methods Following PRISMA guidelines, a systematic literature search was conducted on randomized controlled trials in PubMed, EMBASE, Web of Science and Cochrane Library (the literature was published from database inception through December 16, 2022). Using random effect model and fixed effect model. STATA17.0 software was used to evaluate the quality and heterogeneity of the included research literature. Results The system included 4 randomized controlled trials (485 subjects). The network meta-analysis showed that ceftriaxone had better results than placebo [Mean = 0.87, 95% CI (0.02, 1.71)] and doxycycline [Mean = 1.01, 95% CI (0.03, 1.98)] in FSS scale scores. There was no statistical difference in FSS scale scores of other drugs after treatment. In terms of FSS score results, Ceftriaxone was the best intervention according to the SUCRA value of each treatment (97.7). The analysis of outcome indicators such as Beck Depression Inventory (BDI), Mental-health Scale and Physical-functioning scale showed that there was no statistically significant difference between the antibiotic group and placebo group. Conclusion Ceftriaxone treatment may be the best choice for antibiotic treatment of PTLD, which provides useful guidance for antibiotic treatment of PTLD in the future.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Despite this suggestion, few studies exist investigating treatments to improve a PSLD patient's health-related quality of life (HRQoL) 25 . The positive effects of regular exercise on health are well supported 26 .…”

Section: Introductionmentioning

confidence: 99%

Qualitative Description of the Exertional Symptoms of Participants with Persistent Symptoms of Lyme Disease during a Low Intensity Resistance Training Intervention

McMillin,

Melton,

Murray

et al. 2024

RDHS

View full text Add to dashboard Cite

Introduction: Greater emphasis needs to be placed on approaches to improve the health-related quality of life of patients with persistent symptoms of Lyme disease (PSLD), but little information exists to inform an exercise professional’s expectations of their supervision of resistance training (RT) programs with PSLD patients. In order to build this knowledge base, a secondary qualitative analysis was performed to explore the RT exertional symptoms of PSLD patients that participated in a 4-week study investigating the feasibility of an RT intervention. Methods: Comments regarding exertional symptoms that were recorded in a daily exercise log were the main source of data for this secondary analysis. A manifest content analysis was performed in order to identify recurrent themes of exertional symptoms experienced by this sample of PSLD patients during RT. Results: The reported findings revealed that strain, discomfort, crepitus, tightness, shaking, and control loss were the major themes of exertional symptoms recorded during the RT intervention. Conclusions: These results provide insights intended to inform the expectations of supervisors of exercise (personal trainers, physical therapists, exercise researchers, etc.) when directing RT programming with patients with PSLD.

show abstract

“…FM is characterized by widespread chronic pain persisting for at least three months, with patients frequently experiencing increased sensitivity to pain (hyperalgesia) or pain from typically non-painful stimuli (allodynia) [3]. CLLS, though the least understood among these, shares many symptoms with ME/CFS and other post-viral conditions, as well as with FM [4,5]. Patients with CCDs have persistent and debilitating symptoms [6] coupled with functional impairment [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Complex Chronic Diseases Program: Program Description & Health Outcomes Assessment from a Clinical Data Registry

Meagher,

Magel,

Boulter

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: The Complex Chronic Diseases Program (CCDP) was funded by the BC Ministry of Health to address gaps in health services provision for Complex Chronic Diseases (CCDs). The Program offers medical interventions and education on self-management for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), Fibromyalgia (FM), and Chronic Lyme-Like Syndrome (CLLS). The CCDP Data Registry was created in 2017 for monitoring participant outcomes and program evaluation. Methods: This research outlined the CCDP model of care and analyzed patient-reported questionnaires and clinical data collected longitudinally from consented CCDP Data Registry participants spanning June 2017 through September 2022. T-tests and linear regression modelling were conducted to ascertain changes in symptom presentation across program involvement. These analyses specifically targeted data at the following time points: baseline, 6 months follow-up, and discharge. Results: Data reported in this study represented 668 eligible participants from the 1-year Program. Demographically, the average age was 49 years old (SD=13), 90% were women (n=557), 54% were diagnosed with ME/CFS and FM (n=360), and 36% reported being on long term illness/disability (n=219). Between baseline and discharge, participants with ME/CFS and FM reported improvements in overall physical and mental health, but no significant improvement in other symptom domains such as sleep, fatigue, and pain. The duration of disease at baseline was only related to sleep quality. The previous, more individualized model of care showed better mental health outcomes at 6-months follow-up. Discussion: This analysis showed that CCDP patients experienced relatively severe and persistent symptom presentations. Participants involved in the Program experienced some health benefits at discharge, but further research and interventions are needed to optimize health outcomes. The reliance on self-report of symptoms and the absence of a control group without intervention limit the significance of these findings. A Strategic Direction Plan was developed by the CCDP which emphasized improved training, decentralized services, fast-tracking of eligible individuals, and enhanced education for better patient outcomes.

show abstract

Management of patients presenting with generalized musculoskeletal pain and a suspicion of Lyme disease

Cited by 6 publications

References 61 publications

Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis

Efficacy and safety of antibiotic therapy for post-Lyme disease? A systematic review and network meta-analysis

Qualitative Description of the Exertional Symptoms of Participants with Persistent Symptoms of Lyme Disease during a Low Intensity Resistance Training Intervention

Complex Chronic Diseases Program: Program Description & Health Outcomes Assessment from a Clinical Data Registry

Contact Info

Product

Resources

About